James C Mulloy
Overview
Explore the profile of James C Mulloy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
6106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y, et al.
Blood
. 2021 Oct;
139(3):399-412.
PMID: 34624096
Mixed-phenotype acute leukemia is a rare subtype of leukemia in which both myeloid and lymphoid markers are co-expressed on the same malignant cells. The pathogenesis is largely unknown, and the...
12.
Earnest K, McConnell E, Hassan E, Wunderlich M, Hosseinpour B, Bono B, et al.
Sci Rep
. 2021 Sep;
11(1):19174.
PMID: 34580387
Current classes of cancer therapeutics have negative side effects stemming from off-target cytotoxicity. One way to avoid this would be to use a drug delivery system decorated with targeting moieties,...
13.
Wunderlich M, Manning N, Sexton C, OBrien E, Byerly L, Stillwell C, et al.
Front Oncol
. 2021 Apr;
11:642466.
PMID: 33928030
Immune therapies such as blinatumomab, CD19-directed bispecific CD3 T-cell Engager (BiTE), have resulted in significant improvements in outcomes for relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, up to half of...
14.
Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al.
Cancer Cell
. 2020 Jun;
38(1):79-96.e11.
PMID: 32531268
Fat mass and obesity-associated protein (FTO), an RNA N-methyladenosine (mA) demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the development of effective targeted therapeutics. Here, we report...
15.
Khodoun M, Morris S, Angerman E, Potter C, Schuman R, Wunderlich M, et al.
J Allergy Clin Immunol
. 2019 Dec;
145(3):907-921.e3.
PMID: 31836406
Background: Anaphylaxis is classically mediated by allergen cross-linking of IgE bound to the α chain of FcεRI, the mast cell/basophil high affinity IgE receptor. Allergen cross-linking of the IgE/FcεRI complex...
16.
Rodriguez S, Abundis C, Boccalatte F, Mehrotra P, Chiang M, Yui M, et al.
Leukemia
. 2019 Nov;
34(5):1241-1252.
PMID: 31772299
Timed degradation of the cyclin-dependent kinase inhibitor p27 by the E3 ubiquitin ligase F-box protein SKP2 is critical for T-cell progression into cell cycle, coordinating proliferation and differentiation processes. SKP2...
17.
Wunderlich M, Manning N, Sexton C, Sabulski A, Byerly L, OBrien E, et al.
PLoS One
. 2019 Nov;
14(11):e0225532.
PMID: 31747424
We have previously characterized an acute myeloid leukemia (AML) chemotherapy model for SCID-based immune deficient mice (NSG and NSGS), consisting of 5 days of cytarabine (AraC) and 3 days of...
18.
Melgar K, Walker M, Jones L, Bolanos L, Hueneman K, Wunderlich M, et al.
Sci Transl Med
. 2019 Sep;
11(508).
PMID: 31484791
Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course; however, most patients will relapse because of target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent...
19.
Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al.
Cancer Cell
. 2019 Apr;
35(4):677-691.e10.
PMID: 30991027
FTO, an mRNA N-methyladenosine (mA) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to...
20.
Goyama S, Schibler J, Mulloy J
Exp Hematol
. 2019 Jan;
72:27-35.
PMID: 30690039
Transcription factor RUNX1 plays a crucial role in hematopoiesis and its activity is tightly regulated at both the transcriptional and posttranslational levels. However, translational control of RUNX1 expression has not...